Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Lo

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Advanced Nursing|October 2, 2024
Integrated Health Education Programmes With Physical Activity Among Community-Dwelling Older Adults at Risk of Atherosclerotic Cardiovascular Disease: An Integrative Review of Experimental StudiesFlora M W Lo, Eliza M L Wong, Katherine Ka Wai Lam, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174J B McCrea, A Cribb, T Rushmore, et al.
Journal of Clinical Pharmacology|July 3, 1998
Pharmacokinetics of intravenous and oral losartan in patients with heart failureM W Lo, J Toh, S E Emmert, et al.
Journal of Clinical Pharmacology|October 5, 2001
The pharmacokinetics of enalapril in children and infants with hypertensionT Wells, R Rippley, R Hogg, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|July 1, 1995
The pharmacokinetics of losartan in renal insufficiencyD A Sica, M W Lo, W C Shaw, et al.
Kidney International|March 29, 2026
A prospective multi-center randomized controlled trial preemptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remissionDesmond Y H Yap, Shirley C W Chan, Patrick Y H Wong, et al.
Journal of Clinical Pharmacology|June 27, 2000
PhRMA perspective on population and individual bioequivalenceJ S Barrett, V Batra, A Chow, et al.
Journal of Clinical Pharmacology|June 27, 2000
Update to the PhRMA perspective on population and individual bioequivalenceJ S Barrett, V Batra, A Chow, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|June 5, 2009
Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infectionS K Mak, K Y Lo, M W Lo, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Advanced Nursing|October 2, 2024
Integrated Health Education Programmes With Physical Activity Among Community-Dwelling Older Adults at Risk of Atherosclerotic Cardiovascular Disease: An Integrative Review of Experimental StudiesFlora M W Lo, Eliza M L Wong, Katherine Ka Wai Lam, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174J B McCrea, A Cribb, T Rushmore, et al.
Journal of Clinical Pharmacology|July 3, 1998
Pharmacokinetics of intravenous and oral losartan in patients with heart failureM W Lo, J Toh, S E Emmert, et al.
Journal of Clinical Pharmacology|October 5, 2001
The pharmacokinetics of enalapril in children and infants with hypertensionT Wells, R Rippley, R Hogg, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|July 1, 1995
The pharmacokinetics of losartan in renal insufficiencyD A Sica, M W Lo, W C Shaw, et al.
Kidney International|March 29, 2026
A prospective multi-center randomized controlled trial preemptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remissionDesmond Y H Yap, Shirley C W Chan, Patrick Y H Wong, et al.
Journal of Clinical Pharmacology|June 27, 2000
PhRMA perspective on population and individual bioequivalenceJ S Barrett, V Batra, A Chow, et al.
Journal of Clinical Pharmacology|June 27, 2000
Update to the PhRMA perspective on population and individual bioequivalenceJ S Barrett, V Batra, A Chow, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|June 5, 2009
Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infectionS K Mak, K Y Lo, M W Lo, et al.
Pageof 5